Sellas Vaccine Extends Survival in Hard-to-Treat Blood Cancer Trial
Sellas Life Sciences’ galinpepimut-S vaccine reduced the risk of death by 41% in a Phase 3 AML trial, with median survival of 24 months.
Sellas Life Sciences’ galinpepimut-S vaccine reduced the risk of death by 41% in a Phase 3 AML trial, with median survival of 24 months.
Sellas GPS data is imminent, Maxim keeps Buy/$30 PT. BNTX also in focus.
SELLAS Life Sciences' Phase 3 REGAL trial for GPS in AML patients approaches 80-event threshold with 72 deaths reported, suggesting potential survival benefits as stock surges 100% in December.